In this informative CLDF podcast, Sammy Saab provides a clear, big-picture overview of cirrhosis and portal hypertension, breaking down how clinicians approach this complex condition in today’s evolving healthcare landscape. Rather than focusing on technical details, this discussion highlights the key ways cirrhosis impacts the body and why early recognition, ongoing monitoring, and coordinated care are so important for improving patient outcomes.

The episode emphasizes how cirrhosis is best understood in stages—from earlier phases where lifestyle changes and preventive care can make a meaningful difference, to more advanced stages that require closer management and support. A major theme throughout the conversation is the importance of a multidisciplinary approach, with hepatologists working alongside nutritionists, radiologists, transplant teams, and other specialists to provide comprehensive, patient-centered care.

Listeners will also gain insight into how modern hepatology is evolving, including the growing role of imaging, nutrition, and collaboration across specialties. This high-level overview is ideal for healthcare professionals looking to better understand the broader strategy behind managing cirrhosis and portal hypertension, while staying aligned with current trends in liver disease care and improving long-term patient outcomes.

In this insightful CLDF podcast recorded at the 6th Annual Liver Connect Conference, John Vierling, MD, shares a forward-looking overview of Wilson’s disease and the major shifts shaping its future diagnosis and management. This episode explores why Wilson’s disease remains difficult to recognize, often going undiagnosed for years due to its wide range of symptoms and its ability to mimic more common conditions. The conversation highlights the real-world challenges faced by patients, families, and clinicians, including inconsistencies in care and the impact on quality of life.

Looking ahead, the discussion focuses on the exciting progress being made across genetics, diagnostics, and treatment development. Learn how new research is uncovering a broader understanding of how common Wilson’s disease may actually be, along with emerging technologies that could enable earlier and more accurate detection. The episode also touches on the evolution of treatment approaches, including improvements to existing therapies and the potential for innovative options on the horizon.

This high-level overview is ideal for hepatology providers, gastroenterology clinicians, and advanced practice providers who want to stay informed on where the field is headed—without getting lost in complex clinical detail. Discover why Wilson’s disease is entering a new era of innovation and what that could mean for improving patient outcomes in the years ahead.

In this engaging CLDF podcast episode, Fred Gordon, MD, and Valentina Medici, MD, explore the fundamentals of Wilson’s disease and why it remains one of the most challenging liver conditions to recognize in clinical practice. The conversation focuses on the importance of awareness, highlighting how this rare disease can present in many different ways and often goes overlooked or misdiagnosed.

Listeners will gain a high-level understanding of when to consider Wilson’s disease, why early detection is so important, and how clinicians approach the diagnostic journey. The discussion also touches on the role of family history, the complexities of confirming a diagnosis, and the evolving tools that support better identification of the disease. This episode is ideal for healthcare professionals looking for a clear, accessible overview of Wilson’s disease and its impact on liver health, without getting lost in overly technical details.

In this high-level hepatology update from the 6th Annual Liver Connect Conference, Sujit Janardhan, MD, PhD, provides an overview of how the understanding and management of cirrhosis and portal hypertension are evolving in 2026. The discussion focuses on the big-picture shifts in the field, including earlier identification of patients at risk, updated definitions of disease progression, and how these changes are influencing overall treatment approaches.

Rather than focusing on individual therapies in depth, this session highlights how clinicians are thinking differently about preventing complications, improving long-term outcomes, and using newer, less invasive tools to guide decision-making. It also touches on the broader impact of complications like liver failure, fluid buildup, and cognitive changes, while reinforcing the importance of proactive management and patient-centered care. This overview is ideal for healthcare professionals looking to stay current on the direction of hepatology and the evolving strategies shaping chronic liver disease management.

This educational podcast from the 6th Liver Connect meeting provides a comprehensive overview of the TIPS (transjugular intrahepatic portosystemic shunt) procedure, focusing on patient selection, risk stratification, and evolving techniques to improve outcomes in patients with advanced liver disease. The discussion highlights key indications for TIPS, including recurrent or high-risk variceal bleeding, refractory or recurrent ascites, and select cases of portal vein thrombosis or hepatic venous outflow obstruction such as Budd-Chiari syndrome. Learn how early TIPS intervention can reduce rebleeding risk and improve survival in high-risk patients, as well as when TIPS should be used as salvage therapy or secondary prophylaxis. The episode also explores the importance of frailty assessment, MELD 3.0 scoring, and sarcopenia evaluation in predicting post-TIPS hepatic encephalopathy, along with strategies to optimize patients before the procedure.

Additionally, it reviews absolute contraindications such as heart failure, severe pulmonary hypertension, and uncontrolled infection, emphasizing the need for multidisciplinary decision-making. Finally, emerging data on smaller stent diameters (6–8 mm) are discussed, demonstrating how these innovations may reduce complications while maintaining effective portal decompression.

This episode is essential for clinicians managing portal hypertension, cirrhosis complications, and liver transplant candidates.

In this educational overview, Ethan Weinberg, MD, breaks down the fundamentals of portal hypertension and when to consider TIPS (transjugular intrahepatic portosystemic shunt) in clinical practice. The discussion highlights how clinically significant portal hypertension (CSPH) is diagnosed using both invasive and non-invasive methods, and reviews first-line management with non-selective beta blockers like carvedilol. The video focuses on key indications for TIPS, including variceal bleeding and ascites, emphasizing growing evidence that earlier intervention can improve outcomes, reduce complications, and enhance survival in high-risk patients. It also touches on evolving strategies to optimize patient selection and minimize risks such as hepatic encephalopathy. This high-yield summary is designed for clinicians and advanced practice providers managing cirrhosis and its complications, offering practical insights into when and how to escalate care.

This educational video featuring Dr. Rustgi reviews key updates in hepatology, including HCC surveillance in compensated cirrhosis and the emerging role of liquid biopsies for earlier, more accurate cancer detection. It highlights the limitations of traditional tools like ultrasound and AFP, while introducing advances such as circulating tumor DNA and other minimally invasive biomarkers.

The discussion also covers subclinical portal hypertension and the use of HVPG and non-invasive tools for early risk stratification, along with practical applications across patient populations, including MASLD and post-hepatitis C patients. Additionally, it explores the impact of metabolic disease and obesity on cirrhosis progression, emphasizing the need for multidisciplinary, personalized management strategies.

A concise overview for clinicians looking to stay current on evolving approaches in liver disease and HCC surveillance.

This educational podcast with Dr. Sobia Laique from the 6th Annual Liver Connect meeting reviews key updates in the management of portal hypertension, focusing on improving outcomes beyond first variceal bleed prevention. The discussion highlights the advantages of carvedilol over propranolol, including its dual mechanism and greater reduction in portal pressure, with evidence supporting its role as first-line therapy in many patients.

The episode also covers the Baveno VII criteria, demonstrating how non-invasive tools like liver stiffness and platelet count can safely reduce the need for screening endoscopies. Additionally, it outlines the “beta blocker window,” helping clinicians determine when to initiate or discontinue therapy based on blood pressure, renal function, and signs of decompensation.

A concise, clinically relevant overview for providers managing patients with cirrhosis and portal hypertension.

Explore the latest treatment strategies and emerging trends in metabolic dysfunction–associated steatohepatitis (MASH) with expert insights from Dr. Nadege Gunn. This video covers current FDA-approved therapies for patients with moderate to advanced fibrosis, including Resmetirom (Rezdiffra) and Semaglutide, and explains how lifestyle interventions remain the foundation of care. Learn how to personalize treatment decisions based on patient comorbidities such as obesity and type 2 diabetes, when to initiate GLP-1 therapy versus resmetirom, and how these therapies can be used together in real-world practice. The discussion also highlights current gaps in treatment for early-stage disease and cirrhosis, while offering a forward-looking perspective on combination therapy and the next generation of antifibrotic agents in development. Designed for hepatology and gastroenterology clinicians, this video provides practical, up-to-date guidance to help optimize outcomes for patients with MASH.

Learn best practices for identifying, risk stratifying, and managing patients with metabolic dysfunction–associated steatohepatitis (MASH) in this expert-led webcast featuring insights from Dr. Sammy Saab. As MASH continues to rise as a leading cause of cirrhosis, liver cancer, and liver transplantation, this session explores the evolving clinical approach to evaluation and treatment in the context of the broader spectrum of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Discover why traditional liver enzymes are no longer reliable markers, and how noninvasive tools like FIB-4 scoring, vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), and MRI-PDFF are transforming diagnosis and fibrosis assessment—reducing reliance on liver biopsy. The discussion also highlights when to initiate pharmacologic therapy, including emerging treatments like Resmetirom, and emphasizes the importance of addressing underlying metabolic risk factors such as diabetes, obesity, and cardiovascular disease through a multidisciplinary care model. This video is designed for hepatology and gastroenterology clinicians seeking practical, guideline-aligned strategies to improve outcomes in patients with MASH.